Frequency of Clinical Prognostic Factors and Immunophenotypes for ALK-Positive and ALK-Negative Groups
| Factors . | ALK+ No. (%) . | ALK− No. (%) . | P Value . |
|---|---|---|---|
| Median age (yr) | 30 | 61 | <.002 |
| Age range (yr) | 15-64 | 27-75 | — |
| Age ≤60 yr | 31 (86) | 18 (53) | <.001 |
| Normal serum LDH | 25 (69) | 17 (50) | .097 |
| Good performance status | 26 (72) | 19 (56) | .194 |
| Stage I or II | 17 (47) | 12 (35) | .309 |
| Extranodal sites ≤1 | 29 (81) | 20 (59) | .047 |
| B-cell | 5 (14) | 8 (24) | .256 |
| T-cell | 15 (42) | 17 (50) | .753 |
| Null | 16 (44) | 9 (26) | .246 |
| Total | 36 (51) | 34 (49) | — |
| Factors . | ALK+ No. (%) . | ALK− No. (%) . | P Value . |
|---|---|---|---|
| Median age (yr) | 30 | 61 | <.002 |
| Age range (yr) | 15-64 | 27-75 | — |
| Age ≤60 yr | 31 (86) | 18 (53) | <.001 |
| Normal serum LDH | 25 (69) | 17 (50) | .097 |
| Good performance status | 26 (72) | 19 (56) | .194 |
| Stage I or II | 17 (47) | 12 (35) | .309 |
| Extranodal sites ≤1 | 29 (81) | 20 (59) | .047 |
| B-cell | 5 (14) | 8 (24) | .256 |
| T-cell | 15 (42) | 17 (50) | .753 |
| Null | 16 (44) | 9 (26) | .246 |
| Total | 36 (51) | 34 (49) | — |
Abbreviations: LDH, lactate dehydrogenase; good performance status, Eastern Cooperative Oncology Group (ECOG) score <2.